Profile data is unavailable for this security.
About the company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (OCD) and Spinocerebellar Ataxia (SCA), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for immune-mediated brain disorders. Its portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE) with potential application in neurological disorders, cancer, and autoimmune diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-543.74m
- Incorporated--
- Employees202.00
- LocationBiohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 404-0410
- Websitehttps://www.biohaven.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | 95.77m | -129.19m | 993.77m | 200.00 | -- | 7.04 | -- | 10.38 | -3.65 | -3.65 | 2.70 | 3.71 | 0.3131 | 3.64 | 5.89 | 488,612.30 | -42.24 | -- | -48.91 | -- | 84.41 | -- | -134.90 | -- | 3.39 | -13.25 | 0.00 | -- | 302.66 | -- | -61.53 | -- | -- | -- |
| POINT Biopharma Global Inc | 236.04m | 98.14m | 994.57m | 129.00 | 12.13 | 2.11 | 9.96 | 4.21 | 0.7757 | 0.7757 | 2.36 | 4.46 | 0.5817 | -- | 1,895.27 | 1,829,743.00 | 24.19 | -- | 27.26 | -- | -- | -- | 41.58 | -- | -- | -- | 0.00 | -- | -- | -- | 314.13 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 184.34m | -195.15m | 997.19m | 790.00 | -- | 2.35 | -- | 5.41 | -1.36 | -1.36 | 1.29 | 2.94 | 0.2235 | 3.10 | 6.89 | 233,335.40 | -23.67 | -17.18 | -27.04 | -19.07 | 65.61 | 70.34 | -105.93 | -115.58 | 5.34 | -202.41 | 0.2305 | -- | 20.06 | 36.96 | 3.42 | -- | 45.51 | -- |
| VectivBio Holding AG | 0.00 | -93.74m | 1.02bn | 42.00 | -- | 4.79 | -- | -- | -1.87 | -1.87 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -48.18 | -- | -53.99 | -- | -- | -- | -- | -- | -- | -6.14 | 0.0467 | -- | -- | -- | -7.73 | -- | -- | -- |
| Viridian Therapeutics Inc | 1.65m | -172.33m | 1.02bn | 86.00 | -- | 4.74 | -- | 618.82 | -4.66 | -4.66 | 0.0458 | 8.14 | 0.0058 | -- | 5.09 | 19,232.56 | -60.49 | -58.44 | -65.55 | -64.13 | -- | -- | -10,419.11 | -2,117.74 | -- | -- | 0.0132 | -- | -40.20 | -15.04 | -63.54 | -- | 26.50 | -- |
| Inhibrx Inc | 1.28m | -162.89m | 1.05bn | 141.00 | -- | 69.60 | -- | 823.25 | -3.94 | -3.94 | 0.031 | 0.3471 | 0.0062 | -- | 3.76 | 9,078.02 | -78.52 | -79.44 | -89.96 | -103.32 | -- | -- | -12,725.63 | -872.80 | -- | -7.61 | 0.9307 | -- | -69.69 | -23.55 | -77.61 | -- | -12.53 | -- |
| Biohaven Ltd | 0.00 | -543.74m | 1.06bn | 202.00 | -- | 2.24 | -- | -- | -8.15 | -8.15 | 0.00 | 6.92 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -166.74 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 0.00 | -141.82m | 1.06bn | 41.00 | -- | -- | -- | -- | -2.33 | -2.33 | 0.00 | -0.5919 | 0.00 | -- | -- | 0.00 | -78.38 | -31.61 | -118.94 | -37.90 | -- | -- | -- | -187.05 | -- | -6.99 | 1.51 | -- | -- | -- | -77.77 | -- | -57.83 | -- |
| National Research Corporation | 149.60m | 30.21m | 1.07bn | 491.00 | 35.70 | 14.27 | 29.96 | 7.12 | 1.21 | 1.21 | 6.01 | 3.04 | 1.04 | -- | 9.86 | 304,684.30 | 21.03 | 26.46 | 28.82 | 37.69 | 62.20 | 62.88 | 20.20 | 24.83 | -- | 80.38 | 0.2201 | 51.89 | 2.44 | 5.21 | -15.12 | 8.78 | 15.34 | 16.00 |
| Deciphera Pharmaceuticals Inc | 138.26m | -181.65m | 1.08bn | 300.00 | -- | 2.46 | -- | 7.83 | -2.35 | -2.35 | 1.79 | 5.61 | 0.2959 | 0.3931 | 6.07 | 460,860.00 | -38.88 | -44.40 | -47.56 | -50.94 | 93.58 | -- | -131.38 | -349.01 | 5.37 | -- | 0.00 | -- | 39.41 | -- | 40.35 | -- | 15.68 | -- |
| P3 Health Partners Inc | 1.08bn | -268.75m | 1.09bn | 600.00 | -- | -- | -- | 1.01 | -6.46 | -6.46 | 25.93 | -0.011 | 0.6687 | -- | 11.41 | 1,796,673.00 | -96.35 | -- | -628.63 | -- | 0.0956 | -- | -144.08 | -- | -- | -17.96 | 0.1867 | -- | 64.66 | -- | -72.63 | -- | -- | -- |
| Opko Health Inc. | 912.55m | -291.24m | 1.09bn | 4.20k | -- | 0.702 | -- | 1.19 | -0.3951 | -0.3951 | 1.23 | 2.01 | 0.4077 | 6.98 | 5.46 | 217,481.90 | -13.00 | -6.47 | -14.75 | -7.40 | 33.11 | 34.81 | -31.87 | -12.72 | 1.49 | -20.17 | 0.1413 | -- | -43.42 | 0.7785 | -989.49 | -- | -11.98 | -- |
| Taro Pharmaceutical Industries Ltd | 572.95m | 25.44m | 1.10bn | 1.46k | 43.41 | 0.7661 | 19.19 | 1.93 | 0.677 | 0.677 | 15.24 | 38.36 | 0.2658 | 1.39 | 2.55 | -- | 1.18 | 1.85 | 1.46 | 2.21 | 46.83 | 56.82 | 4.44 | 6.99 | 2.88 | -- | -- | -- | 2.07 | -2.85 | -56.33 | -34.53 | -9.58 | -- |
| Immunitybio Inc | 586.00k | -430.08m | 1.11bn | 703.00 | -- | -- | -- | 1,889.76 | -1.05 | -1.05 | 0.0014 | -1.21 | 0.0016 | -- | 0.2188 | 808.28 | -117.58 | -94.40 | -- | -212.70 | -- | -- | -73,533.27 | -30,976.64 | -- | -5.89 | 3.86 | -- | -74.30 | 39.77 | -20.12 | -- | 23.34 | -- |
| NewAmsterdam Pharma Company NV | 104.56m | -83.70m | 1.11bn | 17.00 | -- | 2.14 | -- | 10.62 | -1.02 | -1.02 | 1.28 | 6.35 | -- | -- | -- | 6,150,516.00 | -- | -- | -- | -- | -- | -- | -80.05 | -- | -- | -0.3754 | 0.0002 | -- | -- | -- | -172.92 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -94.51m | 1.11bn | 83.00 | -- | 11.21 | -- | -- | -3.21 | -3.21 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -65.75 | -- | -72.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -96.86 | -- | -- | -- |
Data as of May 26 2023. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD
55.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 1919 Investment Counsel LLCas of 31 Mar 2023 | 5.62m | 8.24% |
| Janus Henderson Investors US LLCas of 31 Mar 2023 | 5.23m | 7.66% |
| SSgA Funds Management, Inc.as of 31 Mar 2023 | 4.55m | 6.67% |
| Suvretta Capital Management LLCas of 31 Mar 2023 | 3.85m | 5.64% |
| BlackRock Fund Advisorsas of 31 Mar 2023 | 3.83m | 5.62% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2023 | 3.65m | 5.36% |
| Armistice Capital LLCas of 31 Mar 2023 | 3.12m | 4.58% |
| RP Management LLC (Investment Management)as of 31 Mar 2023 | 2.94m | 4.31% |
| Point72 Asset Management LPas of 31 Mar 2023 | 2.72m | 3.99% |
| Holocene Advisors, LPas of 31 Mar 2023 | 2.04m | 3.00% |
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
